POSB38 Developing a Cost-Effectiveness Analysis for Nivolumab for the Adjuvant Treatment of Patients with Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in the Absence of Overall Survival Data
Abstract
Authors
A Amadi K Toor E Keeney H Thom P Singh I Kim M Venkatachalam